IbogaBaseThe Iboga Evidence Base
Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Evidence

Traumatic brain injury

LAST REVIEWED 2026-05-18 · 346 SOURCES · 0 CORRECTIONS

A 30-person veteran prospective observational study and later neurophysiology work drew attention and require side-by-side design-limit explanation.

Confidence: ModerateSource type: Study
Evidence level
notable open label human signal
Sample sizes
The best-known Nature Medicine report involved 30 male special operations veterans.
Design quality
Open-label observational data can generate hypotheses but cannot establish broad efficacy.
Outcomes
Disability, cognition, PTSD symptoms, depression, anxiety, sleep, and quality of life are separate outcomes.
Limitations
Small sample, male veteran population, Mexico treatment setting, concurrent supports, selection effects, and short follow-up.
Safety signals
Screening, cardiac monitoring, magnesium context, psychiatric history, and follow-up.
What is not proven
Ibogaine is not proven as a general TBI treatment.
Best next source
Nature Medicine 2024 magnesium-Ibogaine veteran study and Nature Mental Health 2025 follow-up.